Evidence — provided by a combination of amyloid-β and tau PET examinations — of advanced Alzheimer’s disease pathological changes in the brain in cognitively unimpaired individuals is strongly associated with short-term (3–5 years) cognitive decline. Thus, amyloid-β and tau PET have high clinical relevance.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jansen, W. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015). A meta-analysis showing that age and APOE genotype are the main risk factors for an abnormal amyloid-β PET scan.
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1993). This paper reports a post-mortem staging system of neurofibrillary tau pathology, which increases with advancing age.
Ossenkoppele, R. et al. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022). A Review article that discusses the current state of tau biomarkers and how they can improve clinical practice and trials.
Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–556 (2018). A consensus paper of a research framework proposing a biomarker-based definition of AD.
Dubois, B. et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484–496 (2021). A consensus paper proposing that the term AD should be restricted to symptomatic individuals.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Hansson, O. et al. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. https://doi.org/10.1038/s41591-022-02049-x (2022).
Rights and permissions
About this article
Cite this article
Amyloid-β and tau PET scans predict clinical progression in cognitively unimpaired people. Nat Med 28, 2267–2268 (2022). https://doi.org/10.1038/s41591-022-02071-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02071-z
